ReviewClinical hypertension2020
Highlights of the 2018 Chinese hypertension guidelines.
Review in Clinical hypertension, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 3 syntheses or guidelines pooled it, 103 citations in OpenAlex.
- A Systematic Literature Review and Network Meta-analysis of Azilsartan Medoxomil Compared to Other Anti-hypertensives Efficacy in Lowering Blood Pressure Amongst Mild to Moderate Hypertensive Patients.Advances in therapy · 2024Pooled it
- Efficacy of angiotensin receptor blockers for nocturnal blood pressure reduction: a systematic review and meta-analysis.Annals of medicine · 2024Pooled it
- Blood pressure lowering effects of β-blockers as add-on or combination therapy: A meta-analysis of randomized controlled trials.Journal of clinical hypertension (Greenwich, Conn.) · 2023Pooled it
- Pharmacokinetics and Bioequivalence of Two Fixed-Dose Combination Tablets of Valsartan/Amlodipine (80/5 Mg) in Healthy Chinese Subjects.Drug design, development and therapy · 2025Trial
- Nocturnal blood pressure rather than night-to-day blood pressure ratio is related to arterial stiffening in untreated young and middle-aged adults with non-dipper hypertension.Journal of clinical hypertension (Greenwich, Conn.) · 2022Trial
- Association between hypertension and incidence of cardiovascular disease events in young adults with type 2 diabetes: a nationwide cohort study.Hypertension research : official journal of the Japanese Society of Hypertension · 2026Article
- Sustained estimated VLDL-C exposure is associated with cardiometabolic multimorbidity and foam cell dysfunction: evidence from prospective cohorts andJournal of geriatric cardiology : JGC · 2026Article
- Hypertension and altitude in community-dwelling older adults: an epidemiological study in northwest China.BMJ open · 2026Article
- Lactation duration and the risk of type 2 diabetes mellitus in parous women: A perspective on socioeconomic status disparity.Journal of advanced research · 2025Article
- The GPX3 rs3828599 genotype in combination with alcohol consumption and age helps identify a high-risk hypertension subgroup for antioxidant intervention.Journal of translational medicine · 2025Article
- The effects of Songling Xuemaikang capsule on vascular remodeling of stage 1 hypertension: a multicenter, randomized placebo-controlled trial protocol.BMC complementary medicine and therapies · 2025Article
- Impact Factors for Trajectories of Medication and Healthy Lifestyle Adherence in Young Adults With Hypertension: A Mixed Methods Study.Journal of clinical hypertension (Greenwich, Conn.) · 2025Article
- Systemic chronic inflammation mediates the effect of per- and polyfluoroalkyl substances exposure on the risk of nonalcoholic fatty liver disease: A cross-sectional study among Chinese government employees.Environmental epidemiology (Philadelphia, Pa.) · 2025Article
- Profiles of echocardiographic features associated with blood pressure in patients with hypertension.Journal of human hypertension · 2025Article
- Association between persistent nocturnal sleep duration patterns and carotid intima-media thickness in Chinese patients with type 2 diabetes.Scientific reports · 2025Article
- Highlights of the 2024 Chinese hypertension guidelines.Hypertension research : official journal of the Japanese Society of Hypertension · 2025Review
- Prevalence, numbers and mortality risk of hypertensive patients with depressive symptom in China.BMC cardiovascular disorders · 2025Article
- Remnant cholesterol and its variability independent of low density lipoprotein cholesterol predict metabolic dysfunction associated steatotic liver disease.Scientific reports · 2025Article
- Evaluation of the Efficacy of Sacubitril/Valsartan on Radiofrequency Ablation in Patients with Hypertension and Persistent Atrial Fibrillation.Cardiovascular drugs and therapy · 2025Article
- Diabetes Mellitus and Hyperlipidemia Status Among Hypertensive Patients in the Community and Influencing Factors Analysis of Blood Pressure Control.Journal of clinical hypertension (Greenwich, Conn.) · 2025Article
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBlood pressure (BP) are uncontrolled in over 80% hypertensive population in China, indicating a compelling need for a pragmatic hypertension management strategy. The 2018 Chinese hypertension guidelines issued in 2019, after 3 years revision. During the periods, the latest United States (US) and European guidelines successively published, bringing new thoughts, wisdoms and schemes on hypertension management. This review aims to summarize the highlights of the new Chinese guidelines. MAIN TEXT: Despite the fact that the 2017 US hypertension guidelines changed hypertension definition from ≥140/90 mmHg to 130/80 mmHg, the Chinese hypertension guidelines did not follow suit, and maintained 140/90 mmHg as the cut-point of for diagnosis of hypertension. A combined, cardiovascular risks and BP levels-based antihypertensive treatment algorithm was introduced. Five classes of antihypertensive drugs, including β-blockers were recommended as initiation and maintenance of BP-lowering therapy. Initiating combination therapy, including single pill combination (SPC) was indicated in high-risk patients or those with grade 2 or 3 hypertension. For those with grade 1 hypertension (BP ≥ 140/90 mmHg), an initial low-dose antihypertensive drugs combination treatment could be considered.
conclusionsChina has never stopped exploring the best strategy for improving hypertension control. Based on clinical evidence and expertise, the newest Chinese guidelines and expert consensus will be of help in guiding physicians and practitioners to provide better management of hypertension in China.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.